Thus, treatments that are directly targeting the pathogenesis of tau, which is much closer linked to neurodegeneration and cognitive decline than Aβ (Bennett et al, 2004; Jack et al, 2013; Fleisher et al, 2015; Ossenkoppele et al, 2016; Wang et al, 2016; Jack et al, 2018), might be more likely to result in a clinical benefit. The gene discussed is MAPT; the disease is Mental deterioration.